Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Joo-Hwan | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Kim, In-Ho | - |
dc.contributor.author | Hur, Joon Young | - |
dc.contributor.author | Hwang, Inhwan | - |
dc.contributor.author | Kim, Chan | - |
dc.contributor.author | Kim, Hyo-Jeong | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Park, Kwonoh | - |
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Jung, Joo Young | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Lee, Jae Lyun | - |
dc.date.accessioned | 2022-07-19T05:03:03Z | - |
dc.date.available | 2022-07-19T05:03:03Z | - |
dc.date.created | 2022-04-06 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 0147-0272 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/170151 | - |
dc.description.abstract | Immune checkpoint inhibitors (ICIs) have become a standard treatment for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy. However, the prognostic factors for patients with mUC receiving ICIs are not well established. We retrospectively collected clinical and laboratory data and reviewed the survival outcomes of patients with mUC who were treated with ICIs after platinum-based chemotherapy. We used univariate and multivariable Cox proportional hazard models to identify independent prognostic factors, and the concordance index (C-index) to evaluate the performance of the new prognostic model. In addition, bootstrap analysis was employed for internal validation of the prognostic model. A total of 224 patients were included in the study. With a median follow-up of 10.5 months (interquartile range, 5.1-17.4 months), median overall survival (OS) was 13.6 months (95% confidence interval [CI], 9.7-17.3 months). In multivariable analysis, independent prognostic factors predicting adverse OS were the presence of liver metastasis (LM), hypoalbuminemia, and neutrophil-lymphocyte ratio (NLR) >5. When patients were categorized into 3 risk groups, median OS was not reached (NR) (95% CI, 17.3-NR), 9.5 months (6.8-NR), and 2.9 months (2.3-4.4) for patients with a score of 0, 1, and 2+, respectively. The C-index for the new model was 0.763 (95% CI, 0.739-0.787). A novel prognostic model, including LM, hypoalbuminemia, and NLR, was developed and validated to estimate OS in patients with platinum-refractory disease on second- or subsequent-line ICI therapy. Further investigations, including prospective validation, are needed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Inc. | - |
dc.title | Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hur, Joon Young | - |
dc.identifier.doi | 10.1016/j.currproblcancer.2022.100848 | - |
dc.identifier.scopusid | 2-s2.0-85126992219 | - |
dc.identifier.wosid | 000913232900003 | - |
dc.identifier.bibliographicCitation | Current Problems in Cancer, v.46, no.3, pp.1 - 11 | - |
dc.relation.isPartOf | Current Problems in Cancer | - |
dc.citation.title | Current Problems in Cancer | - |
dc.citation.volume | 46 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | antineoplastic metal complex | - |
dc.subject.keywordPlus | atezolizumab | - |
dc.subject.keywordPlus | durvalumab | - |
dc.subject.keywordPlus | immune checkpoint inhibitor | - |
dc.subject.keywordPlus | nivolumab | - |
dc.subject.keywordPlus | pembrolizumab | - |
dc.subject.keywordPlus | ticilimumab | - |
dc.subject.keywordPlus | platinum | - |
dc.subject.keywordAuthor | Immune checkpoint Inhibitor | - |
dc.subject.keywordAuthor | Overall survival | - |
dc.subject.keywordAuthor | Platinum chemotherapy | - |
dc.subject.keywordAuthor | Prognostic model | - |
dc.subject.keywordAuthor | Urothelial carcinoma | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0147027222000083?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.